Methods and compositions relating to islet cell neogenesis
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-038/10
A61K-038/00
출원번호
US-0943991
(2007-11-21)
등록번호
US-8785400
(2014-07-22)
발명자
/ 주소
Levetan, Claresa S.
Upham, Loraine V.
출원인 / 주소
CureDM Group Holdings, LLC
대리인 / 주소
Pepper Hamilton LLP
인용정보
피인용 횟수 :
1인용 특허 :
38
초록
The present invention provides methods and kits for treating diseases and conditions associated with impaired pancreatic function. The present invention further provides methods of stimulating islet cell neogenesis and stimulating islet cell differentiation from progenitor cells.
대표청구항▼
1. A method of stimulating islet cell neogenesis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a peptide consisting of the amino acid sequence of SEQ ID NO. 4, Human proIslet Peptide 2 (HIP2). 2. The method of claim 1, further comprising
1. A method of stimulating islet cell neogenesis in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a peptide consisting of the amino acid sequence of SEQ ID NO. 4, Human proIslet Peptide 2 (HIP2). 2. The method of claim 1, further comprising administering a therapeutically effective amount of an agent selected from the group consisting of: an immune therapy agent and an additional agent that stimulates islet cell regeneration. 3. The method of claim 2, wherein said immune therapy agent is selected from the group consisting of: anti-CD3 antibodies, sirolimus, tacrolimus, a heat-shock protein 60, an anti-glutamic acid decarboxylase 65 antibody, mycophenolate mofetil alone or in combination with daclizumab, an anti-CD20 agent, rituximab, campath-1H, lysofylline, vitamin D, IBC-VSO vaccine, interferon-alpha, and a vaccine using CD4+CD25+ antigen-specific regulatory T cells. 4. The method of claim 2, wherein said additional agent that stimulates islet cell regeneration is selected from the group consisting of: a Human ProIslet Peptide (HIP) or a HIP-related peptide, amylin, pramlintide, insulin, exendin-4, GIP, GLP-1, GLP-1 receptor agonists, GLP-1 analogs, hamster INGAP peptide and related peptides, liraglutide, and a dipeptidyl peptidase inhibitor which blocks the degradation of GLP-1. 5. A method of treating a disease or condition associated with impaired pancreatic function in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a peptide consisting of the amino acid sequence of SEQ ID NO. 4, Human prolslet Peptide 2 (HIP2). 6. The method of claim 5 wherein said disease or condition associated with impaired pancreatic function is selected from the group consisting of: type 1 diabetes, new onset type 1 diabetes, type 2 diabetes, Latent Autoimmune Diabetes in Adults, pre-diabetes, impaired fasting glucose, fasting hyperinsulinemia, impaired glucose tolerance, insulin resistant syndrome, insulin deficiency, metabolic syndrome, obesity, anorexia, bulimia, neuropathic pain, pancreatitis, pancreatic cancer, hyperlipidemia, hypertriglyceridemia, eating disorders, anovulatory cycles, lack of or diminished insulin production resulting in aberrant glucose metabolism, and polycystic ovarian syndrome. 7. The method of claim 6, wherein said disease or condition associated with impaired pancreatic function is selected from the group consisting of: type 1 diabetes, type 2 diabetes, Latent Autoimmune Diabetes in Adults, pre-diabetes, and metabolic syndrome. 8. The method of claim 5, further comprising administering a therapeutically effective amount of an agent selected from the group consisting of: an immune therapy agent and an additional agent that stimulates islet cell regeneration. 9. The method of claim 8, wherein said immune therapy is selected from the group consisting of: anti-CD3 antibodies, sirolimus, tacrolimus, a heat-shock protein 60, an anti-glutamic acid decarboxylase 65 antibody, mycophenolate mofetil alone or in combination with daclizumab, an anti-CD20 agent, rituxirnab, campath-1H, lysofylline, vitamin D, IBC-VSO vaccine, interferon-alpha, and a vaccine using CD4+CD25+ antigen-specific regulatory T cells. 10. The method of claim 8, wherein said additional agent that stimulates islet cell regeneration is selected from the group consisting of: a Human Prolslet Peptide (HIP) or a HIP-related peptide, amylin, pramlintide, insulin, exendin-4, GIP, GLP-1, GLP-1 receptor agonists, GLP-1 analogs, hamster INGAP peptide and related peptides, liraglutide, and a dipeptidyl peptidase inhibitor which blocks the degradation of GLP-1. 11. The method of claim 8, wherein said disease or condition associated with impaired pancreatic function is selected from the group consisting of: type 1 diabetes, new onset type 1 diabetes, type 2 diabetes, Latent Autoimmune Diabetes in Adults, pre-diabetes, impaired fasting glucose, fasting hyperinsulinemia, impaired glucose tolerance, insulin resistant syndrome, insulin deficiency, metabolic syndrome, obesity, anorexia, bulimia, neuropathic pain, pancreatitis, pancreatic cancer, hyperlipidemia, hypertriglyceridemia, eating disorders, anovulatory cycles, lack of or diminished insulin production resulting in aberrant glucose metabolism, and polycystic ovarian syndrome. 12. The method of claim 11, wherein said disease or condition associated with impaired pancreatic function is selected from: type 1 diabetes, type 2 diabetes, Latent Autoimmune Diabetes in Adults, pre-diabetes, and metabolic syndrome. 13. A method of reducing insulin requirements in a subject in need thereof, comprising administering to said subject a therapeutically effective amount of a peptide consisting of the amino acid sequence of SEQ ID NO. 4, Human proIslet Peptide 2 (HIP2). 14. The method of claim 13, further comprising administering a therapeutically effective amount of an agent selected from the group consisting of: an immune therapy agent and an additional agent that stimulates islet cell regeneration. 15. The method of claim 14, wherein said immune therapy is selected from the group consisting of: anti-CD3 antibodies, sirolimus, tacrolimus, a heat-shock protein 60, an anti-glutamic acid decarboxylase 65 antibody, mycophenolate mofetil alone or in combination with daclizumab, an anti-CD20 agent, rituximab, campath-1H, lysofylline, vitamin D, IBC-VSO vaccine, interferon-alpha, and a vaccine using CD4+CD25+ antigen-specific regulatory T cells. 16. The method of claim 14, wherein said additional agent that stimulates islet cell regeneration is selected from: a Human ProIslet Peptide (HIP) or a HIP-related peptide, amylin, pramlintide, insulin, exendin-4, GIP, GLP-1, GLP-1 receptor agonists, GLP-1 analogs, hamster INGAP peptide and related peptides, liraglutide, and a dipeptidyl peptidase inhibitor which blocks the degradation of GLP-1.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (38)
Iovanna Juan-Lucio,FRX ; Keim Volker,DEX ; Dagorn Jean-Charles,FRX, Antibodies specific for human pancreatitis associated protein.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Delivery of exogenous DNA sequences in a mammal.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Vinik Aaron I. ; Pittenger Gary L. ; Rafaeloff Ronit ; Rosenberg Lawrence,CAX ; Duguid William P.,CAX, Ingap protein involved in pancreatic islet neogenesis.
Vinik Aaron I. ; Pittenger Gary L. ; Rafaeloff Ronit ; Rosenberg Lawrence,CAX ; Duguid William P.,CAX, Ingap protein involved in pancreatic islet neogenesis.
Wigler Michael H. ; Sorge Joseph A., Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using.
Huang Grace P. (Miami FL) Rhode Peter R. (Miami FL) Stinson Jeffrey R. (Davie FL) Wong Hing C. (Ft. Lauderdale FL), Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage.
Morrison Sherie L. ; Herzenberg Leonard A. ; Oi Vernon T., Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric.
Johnson Kevin Stuart,GBX ; Winter Gregory Paul,GBX ; Griffiths Andrew David,GBX ; Smith Andrew John Hammond,GBX ; Waterhouse Peter Michael,AUX, Methods for producing members of specific binding pairs.
McCafferty John,GBX ; Pope Anthony Richard,GBX ; Johnson Kevin Stuart,GBX ; Hoogenboom Henricus Renerus Jacobus Mattheus,GBX ; Griffiths Andrew David,GBX ; Jackson Ronald Henry,GBX ; Holliger Kaspar , Methods for producing members of specific binding pairs.
Boss Michael A. (Slough GBX) Kenten John H. (High Wycombe GBX) Emtage John S. (High Wycombe GBX) Wood Clive R. (Near Fordingbridge GBX), Multichain polypeptides or proteins and processes for their production.
Hoogenboom Hendricus R. J. M. (Cambridge GBX) Baier Michael (Frankfurt DEX) Jespers Laurent S. A. T. (Tervuren BEX) Winter Gregory P. (Cambridge GBX), Production of chimeric antibodies - a combinatorial approach.
Iovanna Juan-Lucio (Marseille FRX) Volker Keim (Heddesheim FRX) Dagorn Jean-Charles (Marseille FRX), Protein associated with acute pancreatitis agents for the screening of acute pancreatitis.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.